Zimbabwe’s medicinal cannabis licensees are navigating a critical renewal cycle, with the Medicines Control Authority of Zimbabwe (MCAZ) warning that permits issued in 2021 are reaching the end of their five‑year validity and late renewal applications will not be accepted. In parallel, the government has promulgated Statutory Instrument 108 of 2026, updating the Dangerous Drugs framework to further regulate production, handling and oversight of medicinal cannabis activities.
Investor angle: Local reporting in 2026 points to emerging value‑addition capacity—processing facilities aimed at extracts and higher‑end pharmaceutical outputs—signalling Zimbabwe’s ambition to move beyond raw cultivation. For CBD/hemp entrepreneurs, this reinforces the need to align with MCAZ requirements, secure timely renewals, and design facilities with export‑grade testing and documentation from day one.